← Russell 3000 cross-section

IART INTEGRA LIFESCIENCES HOLDINGS CORP

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$1.3bn
Revenue TTM
$1.6bn
Net income TTM
$-7m
Free cash flow
$26m
Composite score
42.1
Sector rank
#1871

Valuation

P / E
EV / EBITDA
EV / sales
1.1
FCF yield
1.94%
Earnings yield vs 10-yr
-5.27pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-0.4%
EBITDA margin
ROE
-0.7%
ROIC
4.4%
Revenue growth
1.6%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our Tissue Reconstruction segment generates about 30% of our overall revenue and focuses on wound reconstruction and private label. RESULTS OF OPERATIONS Executive Summary For the three and six months ended June 30, 2026, net income (loss) was $4.5 million and $(0.1) million, or $0.06 and $(0.00) per diluted share, as compared to net losses of $(484.1) million and $(509.4) million, or $(6.31) and $(6.65) per diluted share, for the three and six months ended June 30, 2025. …INTEGRA LIFESCIENCES HOLDINGS CORP, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →